Skip to main content
TipRanks
Go Ultimate75% OFF

Matthew Emmens Insider Profile

4 Followers

Matthew Emmens, Director at Bristol-Myers Squibb, holds ― shares in Bristol-Myers Squibb (Ticker: BMY), holds 200.87K shares in Vertex Pharmaceuticals (Ticker: VRTX), holds 0.00 shares in Incyte (Ticker: INCY).

Matthew Emmens's Trading History

BMY
Bristol-Myers Squibb
Feb 23, 2017DirectorUninformative Buy――
VRTX
Vertex Pharmaceuticals
Nov 20, 2012DirectorInformative Sell453.10K$108.03M
INCY
Incyte
―Director―$0.00

You May Also Like

Matthew Emmens insider profile FAQ

What is the percentage of profitable transactions made by Matthew Emmens?
The percentage of profitable transactions made by Matthew Emmens is 0%.
What is the average return per transaction made by Matthew Emmens?
The average return per transaction made by Matthew Emmens is -36.90%.
What stocks does Matthew Emmens hold?
Matthew Emmens holds: BMY, VRTX, INCY stocks.
What was Matthew Emmens's most profitable transaction?
Matthew Emmens’s most profitable transaction was an Informative Sell of VRTX stock on May 26, 2011. The return on the trade was -19.40%.
What is Matthew Emmens's role in Bristol-Myers Squibb?
Matthew Emmens's role in Bristol-Myers Squibb is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.